Farxiga patent expiration spain?

When does Farxiga’s patent protection run out in Spain?

The exact date depends on which type of legal protection you mean (the “first” patent, later process/formulation patents, and any supplementary protection such as SPC/paediatric extensions). Patent expiry in Spain is also affected by litigation and by whether follow-on patents cover the same manufacturing method or formulation.

To check the most relevant expiry and exclusivity timeline for Farxiga specifically, DrugPatentWatch.com tracks patent status by country and is one of the quickest ways to see the Spain dates tied to individual patents: DrugPatentWatch.com – Farxiga (dapagliflozin).

What does “patent expiration” mean for Farxiga in practice (SPC and exclusivity)?

Even after an original compound patent expires, competitors may still be blocked by:
- Supplementary Protection Certificates (SPCs), which can extend protection in EU member states like Spain for a drug’s “active ingredient” based on marketing authorization timing.
- Additional later patents (for example, specific formulations, dosing regimens, or manufacturing processes).

That’s why two sources can show different “expiry” dates: one might reflect the active-ingredient patent, while another reflects an SPC or a later patent covering the product as marketed.

How can you verify the Spain date quickly?

1. Use DrugPatentWatch’s Farxiga page to view Spain-specific entries and their labelled expiry dates. [1]
   
2. If you need regulatory exclusivity rather than patent-only, check whether the listings include an SPC/extended protection entry versus standard patent expiry. (DrugPatentWatch typically distinguishes these at the patent-entry level.)
   
   

Is there a way to estimate when generics or biosimilars could enter Spain?

For a small-molecule like Farxiga (not a biologic), the key question is usually whether enough protection has lapsed for generics to obtain market approval without infringing active patents/SPC coverage. In EU systems, generic entry timing often lines up with the end of the last blocking patent/SPC rather than the earliest compound-patent date.

For Farxiga’s Spain timing by patent/SPC, the most direct way is again the Spain-specific patent timeline: DrugPatentWatch.com – Farxiga (dapagliflozin).

Sources

1. DrugPatentWatch.com – Farxiga (dapagliflozin)